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PREFACE 
 
Obesity is recognized as a disease of epidemic proportions worldwide; as a 
consequence, a strong demand is now put on the development of novel effective 
therapies for this condition. The current multidimensional treatment of obesity 
includes lifestyle changes, behavioural and surgical approaches, as well as 
pharmacological options. The drugs approved for the clinical treatment of obesity 
are, however, quite few at the moment and not always effective or well tolerated. 
This situation seems to evolve today, since the discovery, over the last decade, of a 
wide range of novel biological targets relevant to food intake and energy metabolism 
and to obesity has stimulated a great research effort in this field. For these reasons, 
several promising molecules are now under evaluation at different experimental 
levels by numerous public and private research centers. 
 
This Hot Topic issue of Mini-Reviews in Medicinal Chemistry has therefore been 
focused on novel approaches to the drug therapy of obesity and collects six updated 
reviews from experts involved in the development of this field. 
The first article, by Chaput et al., is a critical review of the use of two drugs, 
sibutramine and orlistat, currently available to the clinics. The following articles of 
the issue will then cover in detail the families of molecules proposed and studied to 
target specific biological systems involved in the development and maintenance of 
the state of obesity. The contribution by Dozio et al. reviews the hypothalamic 
neuropeptide systems involved in the control of food intake and energy metabolism, 
such as the neuropeptide Y and the melanocortin systems, and the agonist and 
antagonist molecules developed to specifically modulate these targets, acting as anti-
obesity drugs. The mini-review by Cervino et al. reports the state-of-the-art of 
cannabinoid receptor antagonists and their promising use in the treatment of obesity 
and the metabolic syndrome. The molecular biology of leptin, one of the most 
studied adipokines, is reviewed by Correia within the perspective of the potential 
therapeutic actions of recombinant leptin and leptin-related compounds, whereas 
other adipokines and adipocyte targets, useful for the future management of obesity 
and the metabolic syndrome, is the area reviewed by Kralisch et al.. Ghrelin and 
other gastrointestinal peptides involved in the control of food intake, another 
important field of research in the pharmacology of obesity, is the topic covered by 
Tassone et al.. 
 
Obesity is known to arise from the combination of environmental and genetic factors, 
like many highly prevalent chronic degenerative diseases. Thus, together with 
lifestyle changes, a future pharmacological approach will need to combine novel safe 
and effective drugs, several of which are reported or envisioned in this issue, together 
with the study of the specific genetic/genomic pattern of each individual obese 
subject, in the logic of pharmacogenomics. 
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